CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
53 hedge funds and large institutions have $52.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
26% more funds holding
Funds holding: 42 → 53 (+11)
10% less capital invested
Capital invested by funds: $58.4M → $52.7M (-$5.69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.47M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$722K |
| 3 |
Renaissance Technologies
New York
|
+$582K |
| 4 |
Jane Street
New York
|
+$516K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$387K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$660K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$415K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$221K |
| 4 |
Millennium Management
New York
|
-$215K |
| 5 |
VF
Virtu Financial
New York
|
-$54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIS
51
Sound Income Strategies
Ft Lauderdale,
Florida
| – | +$97 | +33 | New |
|
52
CIBC Private Wealth Group
Atlanta,
Georgia
| – | +$147 | +50 | New |
|
CTIC Hedge Fund Activity: Q4 2017 in Review
53 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2017, worth a combined $52.7M — down 9.7% from $58.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CTIC positions and 4 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $2.47M. The largest seller was Vanguard Group, cutting an estimated $660K.
- 53 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $52.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2017, down 9.7% quarter-over-quarter.
- 15 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2017 and 4 closed out, a net change of +11 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2017 was Stonepine Capital Management, an estimated $2.47M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2017 was Vanguard Group, an estimated $660K sold.
Based on aggregated 13F filings for Q4 2017.